Bemiparin
- Generic Name
- Bemiparin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 91449-79-5
- Unique Ingredient Identifier
- PUE0TO3XDR
- Background
Bemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH). Like semuloparin, bemiparin is classified as an ultra-LMH because of its low mean molecular mass of 3600 daltons, which is a unique property of this class . These heparins have lower anti-thrombin activity than the traditional low molecular wei...
- Indication
Bemiparin is indicated in the following cases: To prevent blood clots in the veins after general abdominal surgery in patients with a moderate risk of venous thromboembolism; in the prevention of the thromboembolic disease in non-surgical patients; prevention of clotting in the extracorporeal circuit during hemodialysis; to prevent blood clots in the veins a...
- Associated Conditions
- Extracorporeal Clotting During Hemodialysis, Thromboembolism
- Associated Therapies
- Dialysis therapy
Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly
- Conditions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2011-03-18
- Lead Sponsor
- Rovi Pharmaceuticals Laboratories
- Target Recruit Count
- 60
- Registration Number
- NCT00413088
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau and Fundació Puigvert, Barcelona, Spain
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2012-06-08
- Target Recruit Count
- 39
- Registration Number
- NCT00324558
- Locations
- 🇪🇸
Hospital de Sagunto, Puerto de Sagunto, Valencia, Spain
🇪🇸Hospital Río Hortega, Valladolid, Spain
🇪🇸Hospital de Cruces, Barakaldo, Vizcaya, Spain
Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2012-06-08
- Target Recruit Count
- 402
- Registration Number
- NCT00311896
- Locations
- 🇷🇴
District Emergency Clinical Hospital, Targu-Mures, Romania
🇪🇸Hospital Clínico San Carlos-Madrid., Madrid, Spain
🇪🇸Hospital Santa Creu i Sant Pau, Barcelona, Spain
CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-04-28
- Lead Sponsor
- Rovi Pharmaceuticals Laboratories
- Target Recruit Count
- 526
- Registration Number
- NCT00219973
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.